Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-813-2 | CAS number: 74-83-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
Materials and methods
Test guideline
- Guideline:
- EPA OPP 81-1 (Acute Oral Toxicity)
- GLP compliance:
- yes
Test material
- Reference substance name:
- Bromomethane
- EC Number:
- 200-813-2
- EC Name:
- Bromomethane
- Cas Number:
- 74-83-9
- Molecular formula:
- CH3Br
- IUPAC Name:
- bromomethane
Constituent 1
Test animals
- Species:
- rat
- Sex:
- male/female
Administration / exposure
- Details on oral exposure:
- Comparative Phase
Three groups of five male and five female rats were administered single doses of the microencapsulated Methyl Bromide preparation at dose levels of 80, 120 and 160 mg/kg.
Observations included mortality, body weights and food consumption. After 14 days, necropsy was performed on all rats, major organs were examined and a microscopic examination was carried out on tissues from animals in the comparative phase only.
Results and discussion
Effect levelsopen allclose all
- Dose descriptor:
- LD50
- Effect level:
- 104 mg/kg bw
- Remarks on result:
- other: liquid Methyl Bromide
- Dose descriptor:
- LD50
- Effect level:
- 133 mg/kg bw
- Remarks on result:
- other: microencapsulated Methyl Bromide
- Clinical signs:
- other: Clinical Observations: Several clinical signs observed were limited to those animals that died. Hypoactivity was observed for essentially all animals that died. Ataxia was noted for 23 animals that died. Laboured respiration and hypothermia were observ
- Gross pathology:
- Necropsy:
Gastric abnormalities were observed for 34/35 rats that died during the study. 16 rats from the liquid Methyl Bromide group and 14 from the microencapsulated group had reddened mucosal lining of the stomach. The glandular portion of the stomach was oedematous for 22 animals and the stomach was distended for 5 animals that died. Intestinal abnormalities including dark red or red fluid contents in the intestine were observed for eight dead animals. Clear fluid contents in the thoracic cavity were noted for 4 animals. Dark red kidneys were observed for 26 rats that died. 8 rats had a haemorrhagic thymus gland. Enlarged mesenteric lymph nodes were noted for 2 rats in the liquid Methyl Bromide group.
Gastric abnormalities in the liquid Methyl Bromide group (12 animals) and in the microencapsulated group (13 animals) that survived to day 14 were as follows. The stomach was attached by adhesions to the liver, spleen, abdominal and/or thoracic wall, diaphragm and/or caecum. White material was adhered to the mucosal lining of the nonglandular portion of the stomach for 6 rats in the liquid group and 7 rats in the microencapsulated group. 4 rats had a necrotic area on the liver. - Other findings:
- Microscopic examinations:
Of the rats that died, haemorrhages in the glandular mucosa of the stomach were observed in 12 rats in the liquid group and 6 rats in the microencapsulated group. Submucosal oedema in the forestomach was noted for 8 rats in the liquid group and 9 in the microencapsulated group. One rat also had cytoplasmic vacuolation of the gastric submucosa.
Of the rats that survived to 14 days, squamous cell hyperplasia in the stomach was noted for 11 animals in the liquid group and 11 animals in the microencapsulated group. Ulceration, primarily in the nonglandular portion of the forestomach, was observed in 8 animals in the liquid group and 11 animals in the microencapsulated group. Other, less common gastric lesions included granulomatous inflammation, lymphomoplasmactic cell infiltration, chronic active inflammation and granulocyte infiltration.
Applicant's summary and conclusion
- Conclusions:
- The oral LD50 of liquid Methyl Bromide in rats was 104 mg/kg. The oral LD50 of microencapsulated Methyl Bromide in rats was 133mg/kg. In accordance with the provisions of Council Directive 67/548/EEC, classification as “toxic if swallowed” is required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.